1/3/2011 9:58:51 AM
NASHUA, N.H.--(BUSINESS WIRE)--iCAD, Inc. (NASDAQ:ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, has completed the previously announced acquisition of Xoft, Inc., developer of the Axxent® eBx™ electronic brachytherapy system. The portable Axxent System, which delivers electronically-controlled radiation therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue, is FDA-cleared for the treatment of early stage breast cancer, endometrial cancer and skin cancer, and for the treatment of other cancers or conditions where radiation therapy is indicated. Xoft’s Axxent technology is approved for accelerated partial breast irradiation (APBI), which can be delivered twice daily for five days or it can be administered immediately following the lumpectomy procedure in only a few minutes with one course of therapy, also known as Intraoperative Radiation Therapy (IORT).
comments powered by